Can In Vivo CAR-T Simplify Cell Therapy Manufacturing?

In vivo CAR-T could simplify parts of cell therapy manufacturing by engineering immune cells inside the patient rather than handling their cells outside the body. Our analysis is that the commercial opportunity depends on reliable delivery and clinical evidence, not simply replacing a laboratory workflow with an injection.

What happens outside the body

The National Cancer Institute explains that conventional CAR T-cell therapy changes a patient’s T cells in the laboratory before returning them to the patient. Its CAR T-cell overview describes therapies made from patients’ own T cells. Our commercial interpretation is that moving the engineering step changes the operating model rather than removing the need to make a controlled therapeutic product.

The FDA’s technical CAR T-cell guidance describes manufacturing as involving complex, multi-step procedures. For developers, our suggested comparison is therefore not injection versus factory. It is whether a different delivery platform can reduce patient-specific processing while supporting reproducible treatment.

Transient programming offers one route

AbbVie’s June 2025 announcement described Capstan’s CPTX2309 as a targeted lipid nanoparticle delivering mRNA to CD8-expressing T cells, with transient expression of a CD19-directed receptor. Its August 2025 completion notice confirmed the acquisition and described the candidate as being in Phase 1 at that time.

Our interpretation is that transient programming makes the relationship between exposure, cellular activity and clinical response an important diligence question. A delivery mechanism does not establish durable remission. We would ask developers to distinguish the intended biological effect from outcomes actually demonstrated in patients.

A viral platform changes the comparison

AstraZeneca’s March 2025 acquisition announcement described EsoBiotec’s ENaBL platform as using targeted lentiviruses to deliver genetic instructions to immune cells, presenting reduced manufacturing complexity as a potential advantage. The company confirmed completion in May 2025.

These announcements describe different delivery technologies, not a head-to-head comparison. Our analysis would evaluate targeting, expression, dose control and safety separately for each programme. Neither corporate ownership nor a shorter proposed workflow should substitute for clinical evidence, and these historical notices do not establish today’s development stage.

Regulatory work remains product-specific

The FDA’s CAR T-cell development guidance addresses manufacturing controls, toxicology, clinical study design and analytical comparability. Its scope concerns ex vivo-manufactured CAR T-cell products and oncology studies. We would not treat that scope as establishing a pathway for in vivo engineering or autoimmune indications. Its gene-therapy follow-up guidance recommends risk assessment and explains that not every gene therapy requires long-term follow-up observations.

Our recommendation is to assess the actual product and delivery method rather than assume a universal monitoring requirement. For investors, we would examine how process changes affect the evidence supporting a programme. Manufacturing simplicity and regulatory simplicity are different propositions; neither should be inferred from a platform description.

Access is not just a manufacturing problem

In June 2025, the FDA eliminated REMS requirements for specified approved autologous CAR T-cell therapies while retaining safety information in product labelling. That decision concerns those products, not an approval of experimental in vivo approaches.

Our conclusion is conditional: in vivo engineering could change the economics of delivery, but savings, wider access and durable benefit need their own evidence. We would prioritise clinical response, adverse events, process consistency and the complete treatment pathway before accepting commercial forecasts.

Related reporting: EMBL Images Ribosome Assembly Inside Human Cells; GSK Announces US Approval of Hibsago for Selected Hepatitis B Patients; Jemperli Gains US Accelerated Approval for MSI-H/dMMR Rectal Cancer; AlphaGenome Can Rank Variants Fast but Validation Still Decides; GSK Reports Early Global Lung Cancer Results for Ris-Rez.